Breast Cancer
A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/HR+ Advanced or Metastatic Breast Cancer and Retreatment with T-DXd(DESTINY-Breast Guide)Protocol: DS8201-0004-CIS-MA
- Details
ClinicalTrials.gov ID:
NCT07683754
Diagnosis Type:
NA
USOR Number:
- Address
,
P: